1 / 21

A case study on commercializing science from academic lab

A case study on commercializing science from academic lab. CENG 109 Class 25 . Class Agenda. Case study on Langer Lab at MIT Role-playing on Cool Lab at UST. Case study: Langer Lab @ MIT . Langer Lab performance in 2003. Examples of Langer Lab Spinout. Harvard Business School Case Study.

vito
Download Presentation

A case study on commercializing science from academic lab

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. A case study on commercializing science from academic lab CENG 109 Class 25

  2. Class Agenda • Case study on Langer Lab at MIT • Role-playing on Cool Lab at UST

  3. Case study: Langer Lab @ MIT Langer Lab performance in 2003

  4. Examples of Langer Lab Spinout Harvard Business School Case Study

  5. Questions • How does Langer Lab successfully commercialize science? • What should the university do to grow the scientific capital? • What should the government do to facilitate the transfer science to industry? • How should the businesses based on the scientific capital be managed? Harvard Business School Case Study

  6. From lab research to science-based businesses “What excites me, personally, is that you can use science as a tool to create things that can change the world. Everything we’ve tried to do is to make discoveries that will affect human life.” - Professor Robert Langer Four elements on an ideal research project: • A huge idea : recognizing critical need of a society; met by inventing a platform product • A seminal paper: establish the underlying science of product conecpt • A blocking patent: preventing future entry by competitors • In vivo studies: results to demonstrate efficacy of research Harvard Business School Case Study

  7. Timeline for creating AIR® Harvard Business School Case Study

  8. AIR® Concept • Recognize that the particle deposition depends on its aerodynamic diameter Aerodynamic diameter ____________ = actual particle diameter x √ particle density • Large porous particle Has the same aerodynamic Property as small dense particle Picture: Science 276(1868), 1997

  9. Working with Technology Licensing Office

  10. Seminal Paper: Proof of Concept

  11. Animal results Demonstrate technology works in animals Science 276(1868), 1997

  12. Patents and Technology Transfer • MIT: grant 80—100 technology licenses per year  about 10 new biotechnology companies per year Sampling of biotech companies formed out of MIT since 1998 • Akceli: drug discovery arrays • Alnylam: siRNA therapeutics • Advanced inhalation research: aerosol • delivery of drugs • Matritech: bladder cancer detection • MnemoSciences: shape memory polymers • For medical devices • Microbia: antifungal drug discovery • Momenta: polysaccharide drugs • Ribocept: anti-RNA drugs • Cardium: chloresterol transport therapeutics • Sirena: anti-Alzheimer’s drugs • Microchips: chip-based drug delivery • Galenea: anti-schizophrenic drugs 2004 MIT statistics: • 510 technology disclosure • 159 US patents issued • 94 licenses and options granted • 20 companies founded around MIT IP Nelsen, L.L. Journal of Commercial Biotechnology. 11(4):330-336, 2005

  13. The entrepreneurial community • MIT is surrounded by an entrepreneurial community in Cambridge/Boston • Seasoned executives, lawyers, accountants, consultants, real estate managers, investors • “Knowledgeable money” helps fund and guide a start-up • Venture capital funds specialize in biotechnology start-ups Nelsen, L.L. Journal of Commercial Biotechnology. 11(4):330-336, 2005

  14. Network of People Harvard Business School Case Study

  15. Questions • How does Langer Lab successfully commercialize science? • What should the university do to grow the scientific capital? • What should the government do to facilitate the transfer science to industry? • How should the businesses based on the scientific capital be managed? Harvard Business School Case Study

  16. Scenario for Role Playing

  17. Scenario for Role Playing Dr. Cool, an aspiring professor in UST has many ideas on using biotechnologies to solve unmet health care problems. He figures that given the right environment, these ideas can become the next star companies and will save improve the life of millions of people. What should Dr. Cool do to achieve his goals? What are the major challenges? Will the government and university help or hurt his endeavor? (Last HW assignment; due Dec 7; ½ page maximum)

  18. Questions for your role • Dr. Cool: How should you move your ideas forward? Who should you contact? What do you want to gain from the commercialization of science? How should you be involved in the science business? • UST senior management: What is the mission of the university? Does supporting the commercialization of science contradict with this mission? What policies will you set up to encourage / discourage the commercialization of science? • UST technology transfer: What is the purpose of your department in the university? Filing and maintaining patents costs money, how do you determine whether it is worth the effort for a particular technology? How would you protect the interest of the university when a company expresses interests to license a technology from UST?

  19. Questions for your role • Venture capitalist: • What do you consider when you evaluate a technology? • What other factors determine whether you would invest in a proposal based on a science business? • Once you invest in a company, what would you do to ensure that you can gain the most using the best exit strategy? • Established drug company • When would you decide to license a technology from university? • Will you contract a university lab to perform research for developing the key product candidates for your company? • When would you decide to acquire a start-up company? How much would you pay?

  20. Questions for your role • PhD students and postdoctoral researchers • What do you care most when you are in graduate school? • What can you gain or lose from working on a technology to be commercialized? • What experiments do you need to perform? • Your research aims to solve a health problem. Whom should you get advice to make sure your research is on the right track? • HKU medical school collaborators • As a medical doctor, are you interested in working with an engineer / scientist? • What can you gain or lose from such collaboration?

  21. Questions for your role • Hong Kong Govt/ e.g. Funding agency (UGC) • Do you support the commercialization of science? • If yes, how would you demonstrate your commitment? If not, why? • How would your stance change the research funding scheme? Taxation scheme? Other policies? • How can you persuade the public to support your position? • Chinese Government / e.g. Regulatory Agency (SFDA) • Is a knowledge-based economy important for China? • What is lacking right now to provide an environment for knowledge-based industries? • Should the regulations on drug approval be more stringent or less stringent to encourage the development of modern biotechnologies in China?

More Related